ARTICLE | Emerging Company Profile
Xaira’s $1B AI play: de novo antibodies now, causal biology to follow
Xaira will initially aim Baker tech at validated targets; functional genomics and patient data are its plan for “breaking the system” for target discovery
May 7, 2024 9:08 PM UTC
Xaira’s near- and long-term vision for AI-driven reinvention of the R&D process aligns with the respective maturity of its protein design and biological discovery technologies. The company’s Arch- and Foresite-led $1 billion venture round gives it enough dry powder to act on both timescales.
“We’re a long-term thinking company,” Arch Venture Partners’ Bob Nelsen told BioCentury. “We felt like the power of AI was going to change everything, but the biological case was the least understood, and the least fleshed out.”...